Department of Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Department of Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, 43183, Mölndal, Sweden.
Eur J Med Chem. 2022 Jan 5;227:113925. doi: 10.1016/j.ejmech.2021.113925. Epub 2021 Oct 21.
Inhibition of mucosa-associated lymphoid tissue lymphoma translocation protein-1 (MALT1) is a promising strategy to modulate NF-κB signaling, with the potential to treat B-cell lymphoma and autoimmune diseases. We describe the discovery and optimization of (1s,4s)-N,N'-diaryl cyclohexane-1,4-diamines, a novel series of allosteric MALT1 inhibitors, resulting in compound 8 with single digit micromolar cell potency. X-ray analysis confirms that this compound binds to an induced allosteric site in MALT1. Compound 8 is highly selective and has an excellent in vivo rat PK profile with low clearance and high oral bioavailability, making it a promising lead for further optimization.
抑制黏膜相关淋巴组织淋巴瘤易位蛋白-1(MALT1)是调节 NF-κB 信号的一种很有前途的策略,具有治疗 B 细胞淋巴瘤和自身免疫性疾病的潜力。我们描述了(1s,4s)-N,N'-二芳基环己烷-1,4-二胺的发现和优化,这是一种新型的变构 MALT1 抑制剂系列,导致化合物 8 具有单个位数微摩尔的细胞效力。X 射线分析证实,该化合物与 MALT1 中的诱导变构位点结合。化合物 8 具有高度的选择性,在体内大鼠 PK 特征中具有低清除率和高口服生物利用度,使其成为进一步优化的有前途的先导化合物。